Dr. Michael Baltezor
About Dr. Michael Baltezor
Dr. Michael Baltezor is the Chief Scientific Officer at CritiTech with a Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Kansas and 35 years of experience in the pharmaceutical industry.
Dr. Michael Baltezor Chief Scientific Officer
Dr. Michael Baltezor serves as the Chief Scientific Officer at CritiTech. Bringing an extensive background in various aspects of pharmaceutical sciences, Dr. Baltezor joined CritiTech in 2014. He leverages his deep expertise to spearhead scientific and product development initiatives within the organization.
Dr. Michael Baltezor Education and Expertise
Dr. Michael Baltezor holds a Ph.D. and M.S. in Pharmaceutics and Pharmaceutical Chemistry from the University of Kansas. Additionally, he earned a B.S. in Chemistry from Missouri Western State University. His comprehensive academic background underpins a robust professional expertise in pharmaceutical chemistry, product development, analytical chemistry, toxicology, pharmacology, formulation, drug delivery, CMC, regulatory documentation, cGMP, and quality operations.
Dr. Michael Baltezor Career Background
Dr. Michael Baltezor has accrued 35 years of experience in the pharmaceutical industry. His career includes roles at Sandoz, Marion Labs, Quintiles, Aptuit, Medi-Flex, and Cardinal Health. With a focus on various facets of drug development and quality assurance, Dr. Baltezor has significantly contributed to the field through his work in product development, FDA audits, and Phase II and commercial production.
Dr. Michael Baltezor Achievements
Dr. Michael Baltezor has been instrumental in the development of over 20 FDA-approved drugs. Notably, he is the co-inventor of Cardizem CD, a drug that generates over $2 billion in annual sales. His contributions extend to various domains within pharmaceutical sciences, marking significant milestones in drug formulation and regulatory success.